Sebela Ireland v. Prinston Pharmaceutical, No. 18-1036 (Fed. Cir. Apr. 20, 2021)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This appeal arises from several patent infringement actions filed by Sebela1 in the United States District Court for the District of New Jersey against Prinston 2 and Ac- tavis.3 Sebela accused Prinston and Actavis of infringing claims of U.S. Patent Nos. 8,658,663 (’663 patent) and 8,946,251 (’251 patent) , both relating to methods of using paroxetine to treat thermoregulatory dysfunction associ- ated with menopause.4 Following a bench trial, the district court found claims 1, 2, and 5 of the ’663 patent and claim…